U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C10H15N3S
Molecular Weight 209.311
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TALIPEXOLE

SMILES

NC1=NC2=C(CCN(CC=C)CC2)S1

InChI

InChIKey=DHSSDEDRBUKTQY-UHFFFAOYSA-N
InChI=1S/C10H15N3S/c1-2-5-13-6-3-8-9(4-7-13)14-10(11)12-8/h2H,1,3-7H2,(H2,11,12)

HIDE SMILES / InChI
Molecular Formula C10H15N3S
Molecular Weight 209.311
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/8842679

Talipexole is a D2 receptor agonist which was marketed in June 1996 in Japan for the treatment of Parkinson's disease. Clinical trials with talipexole in patients with Parkinson's disease demonstrated statistically significant improvements from baseline for parkinsonian symptoms including akinesia, rigidity, tremor and gait disturbances.

CNS Activity

Originator

Boehringer Ingelheim
130
Curator's Comment: # Boehringer Ingelheim Pharma KG

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2752
 5.8 null [pKi]
Agonist
2752
 7.0 null [pKi]
Agonist
2752
 7.43 null [pKi]
Agonist
2752
 7.09 null [pKi]
Agonist
2752
 7.37 null [pKi]
Agonist
2752
 6.48 null [pKi]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Phase II
1147
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
658 pg/mL
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/1/650168_1169009F1020_1_198_1F.pdf#page=26
0.2 mg single, oral
dose: 0.2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TALIPEXOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
0.95 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/19646081/
0.4 mg single, oral
dose: 0.4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TALIPEXOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
0.89 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/19646081/
0.4 mg single, oral
dose: 0.4 mg
route of administration: Oral
experiment type: SINGLE
co-administered: LEVODOPA
LEVODOPA
 TALIPEXOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4949 pg × h/mL
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/1/650168_1169009F1020_1_198_1F.pdf#page=26
0.2 mg single, oral
dose: 0.2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TALIPEXOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
10.9 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/19646081/
0.4 mg single, oral
dose: 0.4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TALIPEXOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
10.42 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/19646081/
0.4 mg single, oral
dose: 0.4 mg
route of administration: Oral
experiment type: SINGLE
co-administered: LEVODOPA
LEVODOPA
 TALIPEXOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
5.1 h
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/1/650168_1169009F1020_1_198_1F.pdf#page=26
0.2 mg single, oral
dose: 0.2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TALIPEXOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
12.29 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/19646081/
0.4 mg single, oral
dose: 0.4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TALIPEXOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
10.65 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/19646081/
0.4 mg single, oral
dose: 0.4 mg
route of administration: Oral
experiment type: SINGLE
co-administered: LEVODOPA
LEVODOPA
 TALIPEXOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
60.6%
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/1/650168_1169009F1020_1_198_1F.pdf#ppage=28
TALIPEXOLE plasma
Homo sapiens
Doses

Doses

DosePopulationAdverse events​
1.2 mg 3 times / day multiple, oral
Recommended
Dose: 1.2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.2 mg, 3 times / day
Sources:
https://www.rad-ar.or.jp/siori/english/kekka_plain.cgi?n=981
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: FED
Sources:
https://www.rad-ar.or.jp/siori/english/kekka_plain.cgi?n=981
Disc. AE: Sudden onset of sleep, Neuroleptic malignant syndrome...
AEs leading to
discontinuation/dose reduction:
Sudden onset of sleep
Neuroleptic malignant syndrome
Hallucination
Delusion
Delirium
Sources:
https://www.rad-ar.or.jp/siori/english/kekka_plain.cgi?n=981
2.4 mg 1 times / day multiple, oral
Studied dose
Dose: 2.4 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2.4 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7913738/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/7913738/
Disc. AE: Sedation, Dizziness...
AEs leading to
discontinuation/dose reduction:
Sedation (grade 3, 30.8%)
Dizziness (grade 3, 30.8%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/7913738/
AEs

AEs

AESignificanceDosePopulation
Delirium Disc. AE
1.2 mg 3 times / day multiple, oral
Recommended
Dose: 1.2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.2 mg, 3 times / day
Sources:
https://www.rad-ar.or.jp/siori/english/kekka_plain.cgi?n=981
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: FED
Sources:
https://www.rad-ar.or.jp/siori/english/kekka_plain.cgi?n=981
Delusion Disc. AE
1.2 mg 3 times / day multiple, oral
Recommended
Dose: 1.2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.2 mg, 3 times / day
Sources:
https://www.rad-ar.or.jp/siori/english/kekka_plain.cgi?n=981
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: FED
Sources:
https://www.rad-ar.or.jp/siori/english/kekka_plain.cgi?n=981
Hallucination Disc. AE
1.2 mg 3 times / day multiple, oral
Recommended
Dose: 1.2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.2 mg, 3 times / day
Sources:
https://www.rad-ar.or.jp/siori/english/kekka_plain.cgi?n=981
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: FED
Sources:
https://www.rad-ar.or.jp/siori/english/kekka_plain.cgi?n=981
Neuroleptic malignant syndrome Disc. AE
1.2 mg 3 times / day multiple, oral
Recommended
Dose: 1.2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.2 mg, 3 times / day
Sources:
https://www.rad-ar.or.jp/siori/english/kekka_plain.cgi?n=981
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: FED
Sources:
https://www.rad-ar.or.jp/siori/english/kekka_plain.cgi?n=981
Sudden onset of sleep Disc. AE
1.2 mg 3 times / day multiple, oral
Recommended
Dose: 1.2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.2 mg, 3 times / day
Sources:
https://www.rad-ar.or.jp/siori/english/kekka_plain.cgi?n=981
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: FED
Sources:
https://www.rad-ar.or.jp/siori/english/kekka_plain.cgi?n=981
Dizziness grade 3, 30.8%
Disc. AE
2.4 mg 1 times / day multiple, oral
Studied dose
Dose: 2.4 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2.4 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7913738/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/7913738/
Sedation grade 3, 30.8%
Disc. AE
2.4 mg 1 times / day multiple, oral
Studied dose
Dose: 2.4 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2.4 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7913738/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/7913738/
PubMed

PubMed

TitleDatePubMed
The neuroprotective effect of talipexole from paraquat-induced cell death in dopaminergic neuronal cells.
2010-12
[Dopaminergic neuroprotection and reconstruction of neural network tiara].
2010-10
Effect of bromocriptine on the severity of ovarian hyperstimulation syndrome and outcome in high responders undergoing assisted reproduction.
2010-05
Oxidative neurodegeneration is prevented by UCP0045037, an allosteric modulator for the reduced form of DJ-1, a wild-type of familial Parkinson's disease-linked PARK7.
2009-11-05
Pharmacokinetic profile of talipexole in healthy volunteers is not altered when it is co-administered with Madopar (co-beneldopa).
2009-06
Effective control of catatonia in Parkinson's disease by electroconvulsive therapy: a case report.
2009-02
Oxidative stress induction of DJ-1 protein in reactive astrocytes scavenges free radicals and reduces cell injury.
2009-01-15
Bromocriptine, a dopamine D(2) receptor agonist with the structure of the amino acid ergot alkaloids, induces neurite outgrowth in PC12 cells.
2008-11-19
The frequency of cardiac valvular regurgitation in Parkinson's disease.
2008-05-15
Clinical characteristics of restless legs syndrome in end-stage renal failure and idiopathic RLS patients.
2008-04-30
Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria?
2008-03
Dopamine receptor agonists reverse behavioral abnormalities of alpha-synuclein transgenic mouse, a new model of Parkinson's disease.
2008-02-15
Pharmacological modulation of dopaminergic brain activity and its reflection in spectral frequencies of the rat electropharmacogram.
2008
Mechanism of decongestant activity of alpha 2-adrenoceptor agonists.
2008
MPP(+)-induced cytotoxicity in neuroblastoma cells: Antagonism and reversal by guanosine.
2007-09
Pre-junctional alpha2-adrenoceptors modulation of the nitrergic transmission in the pig urinary bladder neck.
2007
alpha2-adrenoceptor agonists as nasal decongestants.
2007
Antagonistic activity of ascorbic acid (vitamin C) on dopaminergic modulation: apomorphine-induced stereotypic behavior in mice.
2006
Immunohistochemical and functional evidence for a noradrenergic regulation in the horse penile deep dorsal vein.
2004-12
Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor.
2004-10-11
Drug treatment of Parkinson's disease.
2004-09
An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder.
2004-05-01
Practice parameters for the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder.
2004-05-01
Blood pressure and alpha-vascular reactivity in hypertensive rats treated with amlodipine and dietary Ca.
2004-04-05
Effects of an alpha2-adrenoceptor agonist in nasal mucosa.
2003-10
Repeated administration of methamphetamine causes hypersensitivity of D2 receptor in rat ventral tegmental area.
2003-08-21
Paraquat leads to dopaminergic neural vulnerability in organotypic midbrain culture.
2003-08
Piribedil enhances frontocortical and hippocampal release of acetylcholine in freely moving rats by blockade of alpha 2A-adrenoceptors: a dialysis comparison to talipexole and quinelorane in the absence of acetylcholinesterase inhibitors.
2003-04
Inhibitory effects of D2 agonists by striatal injection on excessive release of dopamine and hyperactivity induced by Bay K 8644 in rats.
2003
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor.
2002-11
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
2002-11
Alpha2-adrenoceptor ligands inhibit alpha1-adrenoceptor-mediated contraction of isolated rat arteries.
2002-08
Prolonged drug-induced hypothermia in experimental stroke.
2002-06-20
Impaired endothelial alpha-2 adrenergic receptor-mediated vascular relaxation in the fructose-fed rat.
2002-03
Influence of sildenafil on central dopamine-mediated behaviour in male rats.
2002-02-15
Intranasal application of the alpha2-adrenoceptor agonist BHT-920 produces decongestion in the cat.
2002-01-05
Neuroleptic-like profile of the cannabinoid agonist, HU 210, on rodent behavioural models.
2002-01
alpha(2)-adrenoceptor antagonist properties of OPC-28326, a novel selective peripheral vasodilator.
2001-10
Nonlinear analysis of partial dopamine agonist effects on cAMP in C6 glioma cells.
2001-08-08
Identification of the dopamine autoreceptor in the guinea-pig retina as D(2) receptor using novel subtype-selective antagonists.
2001-08
Modulation of ligand responses by coupling of alpha(2A)-adrenoceptors to diverse G(alpha)-proteins.
2001-05-01
[A-56-year-old woman with parkinsonism, whose mother had Parkinson's disease].
2001-05
Analysis of ligand activation of alpha 2-adrenoceptor subtypes under conditions of equal G alpha protein stoichiometry.
2001-05
Release and aggregation of cytochrome c and alpha-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole.
2001-04-06
Postjunctional alpha(2C)-adrenoceptor contractility in human saphenous vein.
2001-02-16
Receptor reserve analysis of the human alpha(2C)-adrenoceptor using.
2001-01-12
Patents

Patents

JP2007517067A
31

Sample Use Guides

In Vivo Use Guide
Initially 0.2 or 0-4 mg/day, increased by 0.4 mg every week (usual maintenance dosage 1.2 to 3.6 mg/day) Below 0.8 mg/day, once a day; 0.8 to 1.2 mg/day, twice a day; over 1.2 mg/day, 3 times a day
Route of Administration: Oral
In Vitro Use Guide
Talipexole at low concentration (0.1-1 mM) significantly inhibited the accumulation of cytochrome c in the cytosolic fraction of human neuroblastoma SH-SY5Y cells
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:49:30 GMT 2025
Edited
by admin
on Mon Mar 31 18:49:30 GMT 2025
Record UNII
7AM2J46Z1Y
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TALIPEXOLE
INN   MI   WHO-DD  
INN  
Official Name English
TALIPEXOLE [MI]
Preferred Name English
6-ALLYL-2-AMINO-5,6,7,8-TETRAHYDRO-4H-THIAZOLO(4,5-D)AZEPINE
Systematic Name English
talipexole [INN]
Common Name English
Talipexole [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C66884
Created by admin on Mon Mar 31 18:49:30 GMT 2025 , Edited by admin on Mon Mar 31 18:49:30 GMT 2025
Code System Code Type Description
MERCK INDEX
m10441
Created by admin on Mon Mar 31 18:49:30 GMT 2025 , Edited by admin on Mon Mar 31 18:49:30 GMT 2025
PRIMARY Merck Index
WIKIPEDIA
TALIPEXOLE
Created by admin on Mon Mar 31 18:49:30 GMT 2025 , Edited by admin on Mon Mar 31 18:49:30 GMT 2025
PRIMARY
SMS_ID
100000082998
Created by admin on Mon Mar 31 18:49:30 GMT 2025 , Edited by admin on Mon Mar 31 18:49:30 GMT 2025
PRIMARY
EVMPD
SUB10805MIG
Created by admin on Mon Mar 31 18:49:30 GMT 2025 , Edited by admin on Mon Mar 31 18:49:30 GMT 2025
PRIMARY
DRUG CENTRAL
2558
Created by admin on Mon Mar 31 18:49:30 GMT 2025 , Edited by admin on Mon Mar 31 18:49:30 GMT 2025
PRIMARY
MESH
C024763
Created by admin on Mon Mar 31 18:49:30 GMT 2025 , Edited by admin on Mon Mar 31 18:49:30 GMT 2025
PRIMARY
FDA UNII
7AM2J46Z1Y
Created by admin on Mon Mar 31 18:49:30 GMT 2025 , Edited by admin on Mon Mar 31 18:49:30 GMT 2025
PRIMARY
PUBCHEM
5374
Created by admin on Mon Mar 31 18:49:30 GMT 2025 , Edited by admin on Mon Mar 31 18:49:30 GMT 2025
PRIMARY
CAS
101626-70-4
Created by admin on Mon Mar 31 18:49:30 GMT 2025 , Edited by admin on Mon Mar 31 18:49:30 GMT 2025
PRIMARY
NCI_THESAURUS
C152496
Created by admin on Mon Mar 31 18:49:30 GMT 2025 , Edited by admin on Mon Mar 31 18:49:30 GMT 2025
PRIMARY
EPA CompTox
DTXSID8046321
Created by admin on Mon Mar 31 18:49:30 GMT 2025 , Edited by admin on Mon Mar 31 18:49:30 GMT 2025
PRIMARY
ChEMBL
CHEMBL279085
Created by admin on Mon Mar 31 18:49:30 GMT 2025 , Edited by admin on Mon Mar 31 18:49:30 GMT 2025
PRIMARY
INN
5973
Created by admin on Mon Mar 31 18:49:30 GMT 2025 , Edited by admin on Mon Mar 31 18:49:30 GMT 2025
PRIMARY
Related Record Type Details
ALPHA-2A ADRENERGIC RECEPTOR
TARGET -> AGONIST
MATE-2
TRANSPORTER -> INHIBITOR
Structure of TALIPEXOLE DIHYDROCHLORIDE
SALT/SOLVATE -> PARENT
D(2) DOPAMINE RECEPTOR
TARGET -> AGONIST
MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1
TRANSPORTER -> INHIBITOR
Related Record Type Details
Structure of TALIPEXOLE
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966